Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and Bevacizumab for Leptomeningeal Metastasis in EGFRm NSCLC
NCT04425681Phase 2Unknown
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Oct 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib, bevacizumab in leptomeningeal metastasis (LM), non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Nanchang University. Status: unknown.
02
Drugs
osimertinibbevacizumab
03
Conditions
leptomeningeal metastasis (LM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04425681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425681.